12 Lyrica Alternatives for Fibromyalgia: Drug and Non-Drug Options

Alternatives to Lyrica (pregabalin) for fibromyalgia fall into two groups: other medications, including duloxetine, milnacipran, sublingual cyclobenzaprine, and amitriptyline; and non-drug approaches, including aerobic and resistance exercise, tai chi, and behavioral therapies such as CBT, ACT, and EAET. Guidelines place non-drug care first.

Medication alternatives

• Duloxetine (Cymbalta), FDA-approved for fibromyalgia
• Milnacipran (Savella), FDA-approved for fibromyalgia
• Sublingual cyclobenzaprine (Tonmya), FDA-approved 2025
• Amitriptyline, used off-label at low doses
• Low-dose naltrexone, off-label, evidence largely negative

Non-drug alternatives

• Aerobic and aquatic exercise, the strongest guideline recommendation
• Resistance training and tai chi
• Cognitive behavioral therapy and acceptance and commitment therapy
• Emotional awareness and expression therapy
• Coach-led behavioral programs delivered through insurance

If Lyrica has left you dizzy, foggy, or heavier than you want to be, or if it simply has not moved your pain much, you are in a common position. This guide walks through what else exists, what the evidence actually shows for each option, and how to raise the conversation with the clinician who prescribes for you.

Key Takeaways

• Pregabalin helps a minority of people substantially: about 1 in 10 to 14 reach at least 50% pain relief who would not have on placebo, and 19% stopped early because of side effects.
• Duloxetine and milnacipran are also FDA-approved, and duloxetine has the largest average benefit of the three older fibromyalgia drugs. Sublingual cyclobenzaprine was approved in August 2025.
• Exercise is the only strongly recommended treatment in the main European fibromyalgia guideline, ahead of every medication.
• Behavioral therapies target the altered central pain processing that defines fibromyalgia, and they carry no drug side-effect burden.
• Do not stop pregabalin abruptly. The label instructs clinicians to taper over one week at minimum, and any switch should be planned with your prescriber.

Why People Look for Alternatives to Lyrica

Pregabalin was the first FDA-approved fibromyalgia drug, cleared in June 2007. It is a Schedule V controlled substance, started at 150 mg per day and titrated to a recommended range of 300 to 450 mg per day.

The benefit is real but narrow. In the most current synthesis of Cochrane evidence, 22% to 24% of people taking pregabalin reached at least 50% pain relief at approved doses, compared with 14% on placebo. That works out to roughly one additional person in every ten to fourteen benefiting substantially because of the drug.

Early benefit may hold six months, but has not been demonstrated past that, and it concentrates on pain rather than on fatigue or sleep.

Side effects are the more common reason people go looking. In the fibromyalgia trials behind the label, dizziness affected 38% and somnolence 20% of participants, with weight gain in 11% and peripheral edema in 6%. Nineteen percent stopped the drug early because of adverse reactions, compared with 10% on placebo.

One safety point before anything else. Pregabalin should not be stopped suddenly. Stopping abruptly can cause withdrawal symptoms including insomnia, nausea, headache, and diarrhea, and in some people increased seizure activity. Every option below is a conversation to have with your prescriber, not a switch to make on your own.

What the Guidelines Actually Recommend First

This surprises most people on a fibromyalgia medication: the drugs are not the headline recommendation.

In the European fibromyalgia recommendations, the only strongly recommended therapy is exercise. Drug treatment, along with psychological and multimodal therapy, is rated only "weak for." The guideline authors note plainly that the effect size is modest for most fibromyalgia treatments. The American College of Rheumatology's patient guidance takes the same line, leading with exercise rather than medication and advising against opioids.

UK guidance goes further. NICE's chronic primary pain guideline, which covers fibromyalgia, recommends supervised group exercise and says clinicians should not start gabapentinoids, opioids, or NSAIDs for this type of pain at all. It does keep antidepressants on the table as an option, and its wording is about not starting these drugs rather than stopping them in people already taking them.

That guidance applies to the UK and sits in tension with US approval of pregabalin, but it tells you how the evidence looks to an independent appraisal body.

None of this means medication is wrong for you. It means the non-drug options in this article are not consolation prizes.

Brain and Nervous-System Alternatives

Fibromyalgia is classified as nociplastic pain, meaning the central nervous system amplifies pain signals rather than ongoing tissue damage driving them. That classification is the reason behavioral approaches belong on this list at all: they target the processing system itself. Lin Health's condition guide for fibromyalgia covers this mechanism in depth.

1. Cognitive Behavioral Therapy (CBT)

Evidence. Cochrane found CBT produces small improvements in pain, mood, and disability at the end of treatment, with effects somewhat larger at six-month follow-up. A fibromyalgia neuroimaging trial found CBT reduced pain interference and catastrophizing more than an education control, with matching changes in brain connectivity.

The honest comparison. One six-month trial did put them head to head, randomizing 168 adults with fibromyalgia to group CBT, to a pregabalin-plus-duloxetine regimen, or to usual care. It found no difference on pain between the three groups, but CBT outperformed the drug regimen on pain catastrophizing and acceptance, and on function and quality of life. A later analysis of the same trial found CBT was also the most cost-effective option.

That pattern is worth sitting with. CBT did not out-reduce the drugs on pain scores. What it changed was how much the pain interfered, which for many people is the thing that actually shapes a day.

2. Acceptance and Commitment Therapy (ACT)

Evidence. A meta-analysis of six fibromyalgia trials found ACT improved quality of life and pain acceptance with large effect sizes maintained at follow-up. One caveat matters: the effect on pain intensity itself was no longer statistically significant at follow-up, and the trials were small. ACT changes your relationship to pain more reliably than it changes pain scores.

The digital option. A self-guided ACT app, Stanza, was tested in a 275-person phase 3 trial where 71% reported meaningful improvement versus 22% on active control. It received FDA authorization through the De Novo pathway in 2023 as a prescription digital therapeutic. The trial was funded by the manufacturer, and coverage remains limited to a small number of plans and states.

3. Emotional Awareness and Expression Therapy (EAET)

EAET works on the link between unprocessed emotional stress and physical symptoms, an approach with more fibromyalgia-specific data behind it than most people expect.

Evidence. In a 230-person randomized trial in adults with fibromyalgia, 22.5% achieved 50% reduction with EAET at six-month follow-up, versus 8.3% with CBT and 12.0% with education. EAET also showed an advantage over CBT on overall symptoms and widespread pain at that point. Against an education control, the pain benefit was significant right after treatment but not at six months. Lin Health's summary of the rationale and evidence for EAET covers the technique in more detail.

Who it may suit. People whose symptoms flare with stress, conflict, or emotionally loaded situations, and people for whom a standard CBT course has already been tried.

4. Coach-Led Behavioral Programs

Items 1 through 3 share a problem: knowing they work does not tell you how to get them. Pain-specialized behavioral therapists are scarce, general talk therapy is often not covered, and most therapists trained in CBT have not been trained in chronic pain specifically.

Coach-led programs exist to close that gap. Rather than a self-guided app or a general therapist, these pair you with a trained recovery coach who delivers protocolized modules built from the modalities above, with weekly live sessions and support in between. Lin Health is built specifically for fibromyalgia and other persistent-symptom conditions, and is covered by most commercial insurance plans.

The multicomponent approach itself has support: combining behavioral, educational, and movement elements multicomponent care reduced pain over 10 to 16 weeks across 25 randomized trials, when measured against all other interventions combined. The same review found no advantage over passive comparators specifically.

Medication Alternatives to Lyrica

5. Duloxetine (Cymbalta)

Duloxetine is a serotonin and norepinephrine reuptake inhibitor, FDA-approved for fibromyalgia in 2008. It is the medication most often tried when pregabalin does not work out.

Evidence. In pooled Cochrane data, 36% reached 50% relief on duloxetine versus 21% to 23% on placebo. In the most recent network meta-analysis comparing fibromyalgia drugs head to head, duloxetine 120 mg ranked first for pain out of every drug compared, and first for depression.

Trade-offs. Nausea, dry mouth, sweating, and constipation are common. Across the SNRI class, 19% discontinued because of side effects versus 10% on placebo, so the tolerability picture is not obviously better than pregabalin's. Duloxetine also requires tapering.

Who it may suit. People whose fibromyalgia comes with depressed mood, and people who want to avoid pregabalin's weight gain and sedation.

6. Milnacipran (Savella)

Milnacipran is the other SNRI approved for fibromyalgia, cleared in 2009. In the United States it is approved only for fibromyalgia and is not marketed as an antidepressant.

Evidence. 27% reached 50% relief versus 18% on placebo, placing it below duloxetine and roughly level with pregabalin. In the underlying Cochrane review, side effects in 86% of participants versus 78% on placebo, with nausea the most common.

Trade-offs. Milnacipran carries an antidepressant-class boxed warning for suicidal thoughts in people 24 and under. The 200 mg dose is notably less well tolerated than 100 mg.

Who it may suit. People who did not tolerate duloxetine but for whom an SNRI mechanism still makes sense, and people whose fatigue is prominent.

7. Sublingual Cyclobenzaprine (Tonmya)

This is the newest option and the one most people have not heard of. The FDA approved Tonmya for fibromyalgia in adults on August 15, 2025, the first new fibromyalgia drug in over fifteen years. It is a low-dose bedtime sublingual tablet, dosed at 2.8 mg for the first two weeks and then 5.6 mg.

Evidence. The approach targets non-restorative sleep as a route to daytime pain. In the pivotal RESILIENT trial of 456 adults, pain fell 1.8 points versus 1.2 on placebo, on a 0 to 10 scale, and secondary measures of sleep, fatigue, and function also improved. Worth knowing: of the three pivotal trials described in the label, one did not separate from placebo.

Trade-offs. The distinctive side effect is local. Oral numbness affected 23% of participants versus under 1% on placebo, with oral discomfort and taste changes also common. It is contraindicated with MAOIs and in several cardiac conditions.

Who it may suit. People whose fibromyalgia is dominated by unrefreshing sleep. Because it is new, no study has yet compared it directly against pregabalin, duloxetine, or milnacipran, so its relative position is genuinely unknown.

8. Amitriptyline (Off-Label)

Amitriptyline is a decades-old tricyclic used off-label at low bedtime doses, typically 10 mg to 25 mg. It is not approved for fibromyalgia in the US or elsewhere, though it appears in guidelines.

Evidence, honestly stated. This is the option where clinical habit and trial evidence disagree most. The Cochrane review found no unbiased evidence of substantial pain relief, with nine small trials and none enrolling 50 participants per arm. The 2025 Cochrane overview rated the evidence very low certainty and flagged likely publication bias. Yet the head-to-head network analysis ranked it first for sleep and fatigue, and it was the only drug whose dropout rate matched placebo.

Adding to the uncertainty, a 2025 meta-analysis focused on sleep outcomes found no significant sleep benefit for amitriptyline, directly contradicting that ranking. Treat amitriptyline as widely used, cheap, sometimes helpful, and poorly evidenced.

Trade-offs. Side effects in 78% versus 47% on placebo: dry mouth, drowsiness, dizziness, and weight gain.

9. Low-Dose Naltrexone (Off-Label)

Low-dose naltrexone, usually 4.5 mg daily, circulates widely in fibromyalgia communities. The evidence has not kept up with the enthusiasm.

Evidence. Meta-analyses pooling a handful of small trials report a statistically significant pain benefit, with authors cautioning about moderate-to-high risk of bias. But the two adequately sized randomized trials both missed their primary pain endpoint. A 99-person Danish trial found LDN did not surpass placebo, and a 12-month trial in 98 women reported no significant difference from placebo at three months.

Where that leaves it. This is the classic pattern of a promising signal in small pilots that does not survive larger, better-controlled testing. Naltrexone is not FDA-approved for any pain indication and must be compounded. It is reasonable to be curious about it and unreasonable to present it as an evidence-backed swap for Lyrica.

Movement-Based Alternatives

Exercise carries the strongest recommendation in fibromyalgia care, which is not the same as being easy when you hurt. The evidence favors starting low and building slowly.

10. Aerobic and Aquatic Exercise

Evidence. Cochrane found that aerobic training probably improves quality of life in adults with fibromyalgia at moderate certainty, and may slightly reduce pain and improve physical function at low certainty. In a 51-trial network meta-analysis of women with fibromyalgia, aquatic exercise ranked highest for short-term pain relief.

What it looks like in practice. Pool-based work, walking, and cycling at roughly two to three sessions a week. Warm-water exercise is often the most tolerable entry point when movement itself triggers flares.

11. Resistance Training

Evidence. The Cochrane review of resistance training in fibromyalgia rests on only five trials in 219 women at low certainty, showing improved function and strength with reduced pain. The stronger signal comes from the 2025 network meta-analysis, where resistance training ranked first for long-term pain and was the only modality producing clinically meaningful improvement over both short and long timeframes.

What it looks like in practice. Gradual, supervised loading. Moderate-to-high intensity resistance work has been studied and found safe in this population, but progression needs to be slower than a general fitness program would prescribe.

12. Tai Chi

Evidence. In a 226-person randomized trial, tai chi matched aerobic exercise or beat it on fibromyalgia symptom scores over a year, with a dose-response by duration: 24 weeks of tai chi beat 12 weeks, though practising twice a week was no better than once. Adherence also ran higher, 62% versus 40% for the aerobic group. A pooled analysis of traditional Chinese exercise reported reduced pain and improved sleep across twelve trials.

Who it may suit. People who have tried and abandoned conventional exercise because of post-exertional flares. The lower intensity and the attention-to-movement component make it more sustainable for many.

How to Talk to Your Doctor About Switching

Bring specifics rather than a request to stop. The questions below tend to move the conversation:

• Name the problem precisely. "The dizziness makes driving unsafe" lands differently than "it isn't working."
• Ask what the switch would look like. Pregabalin needs a taper of at least a week, and cross-tapering to an SNRI has its own sequence.
• Ask which symptom to target. Pain, sleep, fatigue, and mood respond differently to different drugs, which is exactly what the head-to-head analysis concluded.
• Ask for a referral to behavioral pain care, not general therapy. The distinction matters and most patients do not know to ask for it.
• Ask about combining rather than replacing. Behavioral programs run alongside medication. Nothing here requires stopping a drug that is partly helping.

How Lin Health Helps With Fibromyalgia

Fibromyalgia is one of the conditions Lin Health was built around. The program starts from the understanding that after months or years of persistent symptoms, the pain alarm can stay switched on even when tissue has healed, and the nervous system learns to amplify signals from the body. That learned pattern is what behavioral approaches are designed to interrupt.

Lin Health's approach is based on findings from the research described throughout this article: CBT, ACT, EAET, somatic tracking, and pain neuroscience education. It is not the therapy of record in any single trial.

What it does is package those modalities into structured modules delivered by a trained recovery coach, with weekly live sessions, chat support between sessions, and an app for practice. Coaches are trained in persistent symptoms and pain specifically, not general mental health.

Three practical differences from the options above:

• No medications. Lin Health does not prescribe, adjust, or taper anything. It runs alongside whatever your prescriber has you on.
• Insurance covered. In-network with major commercial plans, with the highest coverage in Colorado, Texas, Florida, California, and New York, and additional coverage elsewhere. Most participants pay nothing out of pocket. Lin Health also partners with health systems including Mayo Clinic.
• Short waits. Sign-up is usually followed by a same-day callback to check eligibility, against a mental health system where specialized pain care can take months.

Patients describe the shift in their own words, including Gina's account of recovery. You can also read more on behavioral alternatives for fibromyalgia and how insurance-covered pain programs work.

If Lyrica has not delivered what you hoped and you want to try something that targets the nervous system rather than masking the signal, a coach-led behavioral program may be worth exploring. Check your eligibility to see if Lin Health may help with your fibromyalgia. Most participants are fully covered by insurance, and the first call is usually within a day.

FAQ

What can I take instead of Lyrica for fibromyalgia?

Three other medications are FDA-approved for fibromyalgia: duloxetine (Cymbalta), milnacipran (Savella), and sublingual cyclobenzaprine (Tonmya). Amitriptyline is used off-label. Non-drug options with guideline support include exercise and behavioral therapies. Your prescriber should guide any switch, since pregabalin requires tapering.

Is there anything better than Lyrica for fibromyalgia?

For pain specifically, duloxetine ranked slightly ahead of pregabalin in the most recent head-to-head analysis of fibromyalgia drugs. The differences between approved medications are small. Guidelines rank exercise above all of them, which suggests the more useful question is which combination fits your dominant symptom.

What is the newest treatment for fibromyalgia?

Sublingual cyclobenzaprine (Tonmya) was FDA-approved in August 2025, the first new fibromyalgia drug in more than fifteen years. It is taken at bedtime and targets non-restorative sleep. A prescription digital therapeutic delivering acceptance and commitment therapy received FDA authorization in 2023.

How do I stop taking Lyrica safely?

Only with your prescriber. The FDA label instructs clinicians to taper over at least one week. Stopping abruptly can cause insomnia, nausea, headache, anxiety, sweating, and diarrhea, and can increase seizure risk in some people. Rapid discontinuation is not safer because a replacement is starting.

Can fibromyalgia be treated without medication?

Yes, and guidelines recommend starting there. Exercise carries the only strong recommendation in the main European fibromyalgia guideline. Behavioral therapies including CBT, ACT, and EAET have randomized trial evidence in adults with fibromyalgia. Many people combine non-drug approaches with medication rather than choosing one.

Is CBT effective for fibromyalgia?

Cochrane evidence shows small improvements in pain, mood, and disability, with benefits that tend to persist after treatment ends. Its effect on pain catastrophizing is larger than its effect on pain intensity. The effect size on pain is comparable to fibromyalgia medications, without the side-effect burden.

Does insurance cover fibromyalgia treatment programs?

Often, yes. Mental health parity rules require commercial plans to cover behavioral health at parity with medical care, and programs like Lin Health are in-network with major carriers. The usual barrier is finding a clinician trained in chronic pain rather than the coverage itself.

Does low-dose naltrexone work for fibromyalgia?

The evidence is largely negative. Meta-analyses of small early trials showed a pain benefit, but the two adequately sized randomized trials, one in 2024 and a 12-month trial in 2026, both missed their primary endpoint. It is not FDA-approved for pain and requires compounding.

Is gabapentin the same as Lyrica?

They are in the same drug class and work similarly, but gabapentin is not FDA-approved for fibromyalgia and pregabalin is. Neither is recommended for chronic primary pain under UK guidance. Switching between them is a clinical decision rather than an upgrade.

This article is for informational purposes and is not medical advice. Consult a qualified healthcare provider before starting, stopping, or changing any treatment for fibromyalgia. Do not discontinue pregabalin or any prescribed medication without medical supervision.